TapImmune Inc.
2815 Eastlake Avenue East
Suite 300
Seattle
Washington
98102
United States
Tel: 866-359-7541
Website: http://www.tapimmune.com/
Email: ir@TapImmune.com
161 articles about TapImmune Inc.
-
TapImmune Inc. Release: Presentation At The Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
3/31/2015
-
TapImmune Inc. To Present At The Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" On Thursday March 26, 2015
3/25/2015
-
TapImmune Inc. Appoints David Laskow-Pooley, CEO Of London Pharma, To Its Board Of Directors
3/19/2015
-
TapImmune Inc. Receives $1,000,000 From Strategic Investor
3/10/2015
-
TapImmune Inc. Appoints John Bonfiglio As Strategic Advisor
2/25/2015
-
TapImmune Inc. Appoints Patrick D. Yeramian, MD, Consulting Medical Director To Lead Phase II Clinical Trials In Triple Negative Breast And HER2/neu Breast Cancer
2/23/2015
-
TapImmune Inc. To Present At The 3rd Annual Sachs Bio Partnering & Investment Forum On February 23, 2015
2/20/2015
-
TapImmune Inc.'s CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" For Phase II Trials
2/12/2015
-
TapImmune Inc. Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials
1/12/2015
-
TapImmune Inc. Announces $1,464,000 Million Registered Direct Offering
1/12/2015
-
Published Review and Analyst Report Boost TapImmune Inc. Shares
11/20/2014
-
VGTI Florida To Collaborate With TapImmune Inc. To Advance Targeted Breast And Ovarian Cancer Vaccines Into Phase 2 Clinical Trials
11/19/2014
-
TapImmune Inc. Announces Phase 2 Clinical Trials Collaboration With VGTI Florida To Advance Breast And Ovarian Cancer Vaccines
11/18/2014
-
TapImmune Inc. Provides Update On Polystartâ„¢ Vaccine Platform Applicable To Cancer And Infectious Disease
10/22/2014
-
TapImmune Inc. CEO Provides Update On Corporate Activity And Progression Of Clinical Programs
9/23/2014
-
TapImmune Inc. Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer
9/16/2014
-
TapImmune Inc. Announces $2 Million Registered Direct Offering
8/11/2014
-
TapImmune Inc.'s New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens
8/7/2014
-
TapImmune Inc. Prevails In Legal Dispute With Michael Gardner
7/24/2014
-
TapImmune Inc. Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board
6/13/2014